Category: Brain Tumor

0

#ASCO2017 Randomized, double-blind, phase III trial of a personalized peptide vaccination for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy.

Randomized, double-blind, phase III trial of a personalized peptide vaccination for human leukocyte antigen-A24-positive glioblastoma multiforme patients refractory to temozolomide-based therapy. Sub-category: Central Nervous System Tumors Category: Central Nervous System Tumors Meeting: 2017 ASCO...

0

ASCO 2017 on Twitter #ASCO2017

#ASCO2017 The Annual Meeting brings together more than 30,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Twitter to follow: ASCO‏ Verified account @ASCO  Fabio...

Advances in neuro-oncology imaging. 0

Advances in neuro-oncology imaging.

Nat Rev Neurol. 2017 May;13(5):279-289. doi: 10.1038/nrneurol.2017.44. Epub 2017 Apr 7. Advances in neuro-oncology imaging. Langen KJ1,2, Galldiks N1,3,4, Hattingen E5, Shah NJ1,2,6. Author information Abstract Despite the fact that MRI has evolved to...